SALT LAKE CITY, May 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its BRAC Analysis CDx™ and HRD™ tests in predicting platinum based therapy response for breast cancer patients. Additionally, the company is providing an update on key commercial milestones that underscore its commitment to the field of companion diagnostics.
"Myriad is committed to advancing the science of companion diagnostics and is currently working with approximately 20 different pharmaceutical companies on companion diagnostic programs," said Mark Capone, president of Myriad Genetic Laboratories. "We believe the future of pharmaceuticals depends on providing therapeutics to patients that are tailored to their individual genetic makeup, and we are investing substantial resources to maintain our global leadership position in this field."
Data on BRAC Analysis CDx in Metastatic Breast Cancer PatientsAt this week's ASCO meeting, Myriad will present data supporting BRAC Analysis CDx's ability to predict platinum response in metastatic breast cancer patients. In a trial of 86 patients, the response rates to platinum based therapies (carboplatin and cisplatin) for patients with deleterious mutations detected by BRAC Analysis CDx (the Company's proprietary companion diagnostic test for deleterious mutations and large rearrangements in the BRCA1 and BRCA2 genes) was 54.5 percent compared to only 19.7 percent in the non-carrier group. These data underscore the ability of BRAC Analysis CDx to predict patient response to platinum based therapies in a patient population characterized by low overall response rates. Myriad is making substantial progress toward the commercialization of BRAC Analysis CDx for PARP inhibitors and several of Myriad's commercial pharmaceutical partners have recently made major announcements on the advancement and expansion of their PARP inhibitor programs. Below is a table summarizing the announced, late-stage clinical trials by commercial partners in which Myriad is providing the companion diagnostic test in support of the drug.
|Company||Drug||Clinical Trial Phase/Indications||Timeline||Myriad Test|
|AstraZeneca||olaparib||Phase 3 – platinum sensitive relapsed ovarian cancer||Expect U.S. FDA and EMA approval for platinum sensitive ovarian cancer in||BRAC Analysis CDx™|
|Phase 3 – first line maintenance therapy for ovarian cancer||CY15. Expect to file with the FDA for breast cancer in CY16.|
|Phase 3 – metastatic breast cancer|
|Phase 3 – neoadjuvant breast cancer|
|Phase 3 – adjuvant breast cancer|
|Biomarin||BMN-673||Phase 3 – metastatic breast cancer||NA||BRAC Analysis CDx™|
|AbbVie||veliparib||Phase 3 – neoadjuvant treatment of triple negative breast cancer||NA||BRAC Analysis CDx™|
|Tesaro||niraparib||Phase 3 – platinum sensitive ovarian cancer||NA||BRAC Analysis CDx™|
|Phase 3 – metastatic breast cancer|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV